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Monocyte infiltration into brain parenchyma is typically mediated by a series of molecules lining the endothelial wall of the blood vessel. Monocytes initiate this process by undergoing tethering and rolling via interaction with selectin ligands such as P-selectin glycoprotein ligand-1. 21 The rolling on the vascular wall reduces the velocity of monocytes, allowing them to interact with chemokines to activate G protein coupled receptor and increase their affinity to endothelium via the integrin class of molecules. The increased affinity of monocytes to cell adhesion molecules present on the endothelial cells facilitates the arrest of the movement of monocytes. Monocytes are guided to enter the CNS by the chemoattractant chemokine C-C ligand 2. 22 Then, with the help of proteases such as the matrix metalloproteinases, monocytes can cross the glia limitans and enter the CNS. 23 Amp B significantly increases the amount of pro-inflammatory monocytes in a mouse model of GBM to control tumor growth. 2 Moreover, tumor suppression via cell cycle arrest of transformed cells is the primary mechanism of Amp B-stimulated circulating monocytes, which is different from the many cytotoxic therapies that actively kill transformed cells. 2 Hence, it may take longer to observe a decrease in tumor volume when stimulators of innate immune response such as Amp B are used compared with cytolytic therapies.
Monocytes are crucial in the mechanism by which Amp B promotes the lifespan of mice harboring intracranial glioblastoma, as depleting monocytes with clodronate liposomes abrogates its therapeutic effect. 2 Thus, monitoring the trafficking of these populations of immune cells into the tumor mass may provide a faster way of detecting an innate immune system-related drug response than waiting for changes in tumor volume or lifespan of animals. As monocytes are phagocytic cells, they engulf iron particles. This makes it possible for ultra-small iron oxide nanoparticles (USPIOs) 8 to be used as an MRI contrast agent to detect trafficking of monocytes into tumor mass.
Iron oxide nanoparticles have an iron core coated with dextran or ferucarbotran to reduce its toxicity and facilitate cellular uptake. 9 Once injected into the blood stream, USPIOs are cleared from the plasma by the reticuloendothelial system via receptor endocytosis. 8 USPIOs are typically phagocytosed and stored by circulating monocytes and by cells in the liver as well as bone marrow.
USPIO-MRI is a promising tool to non-invasively track monocytes, since iron oxide nanoparticles have been widely used in humans. Feridex, a larger iron oxide nanoparticle, is an FDA approved contrast agent for liver imaging. 10, 11 Although there has been no FDA approved USPIO as a contrast agent, ferumoxytol is used to treat anemia in patients with end-stage renal failure. 12, 13 Due to its low toxicity, USPIOs have been widely used to study immune cells in other contexts, such as multiple sclerosis 14, 15 and stroke. 16 This wide range of clinical use should enable animal USPIO results to be easily translatable to humans.
We hypothesize that we can use USPIO-MRI to label monocyte trafficking into the region of a brain tumor. This should be able to detect the treatment-associated phenomena of drugs that modulate the innate immune system. To do this, we used Amp B as the test drug, since our previous work has already demonstrated the efficacy of Amp B in reducing GBM growth in mice through stimulating innate immunity. 2 Using an animal model with intracranial GBM and Amp B as the drug, we are the first to show that USPIO imaging can be used to rapidly detect a treatment-associated phenomenon due to activation of the innate immune system.
Materials and Methods

Animals
Ethics were approved by the Animal Care Committee at the University of Calgary. Female severe combined immunodeficient mice (8-10wk, Charles River, CB17 strain) were implanted with 10000 cells of the BT048 BTIC line. This patient-derived BTIC line was described previously 2, 17 ; cells were implanted into the right striatum. 17 The cell line was tested for pathogen and mycoplasma at Charles River and was obtained from the Clark H. Smith Brain Tumor Bank in 2010. We conducted 2 experiments to address our hypothesis. For both experiments, cells were allowed to grow for 35 days, after which the animals were treated daily as guided by previous results. 2 For Experiment 1, animals were treated with 0.2mg/kg Amp B (n=4) or sodium deoxycholate (n=5), the vehicle for Amp B. For Experiment 2, all animals were treated with Amp B (n=4).
MRI Protocol
For both experiments, MRI was performed 42-45 days post-implantation using a 9.4T Bruker system with a 35-mm volume coil. Animals were anesthetized with 2% isoflurane, 30% oxygen, and 70% nitrogen. Three baseline sequences were acquired: T2 weighted (T2w) spin echo (repetition time [TR] = 3000ms, nominal echo time [TE] = 30ms, voxel size = 0.075mm × 0.075mm × 0.5mm), multiecho gradient echo (MEGE) (TR = 1500ms, TE = 3.1, 7.1, 11.1, 15.1, 19.1ms; voxel size =0.15mm × 0.15mm × 0.75mm, flip angle = 30degrees), and T1 weighted (T1w) scan (TR = 500ms, nominal TE = 7ms, voxel size = 0.15mm × 0.15mm × 0.75mm). The slices from these 3 scans were coregistered. A cannula was then placed into the tail vein through which gadolinium (Gd; Magnevist) was injected at a dose of 0.1 mmol/kg as a 100-μL bolus. The T1w scan was then repeated to assess blood-brain barrier (BBB) leakage. Following the T1w scan, ferumoxytol (30mg/kg) was injected as a 100-μL bolus through the same cannula. The MEGE and T1w sequences were repeated 24 hours post ferumoxytol injection.
Histology
For Experiment 1, animals were immediately sacrificed after MRI and were perfused with phosphate buffered saline and then 4% paraformaldehyde. The brains were removed and were paraffin embedded. Tissues were cut into 8-μm paraffin slices; 3,3ʹ-diaminobenzidine (DAB)-enhanced Perl's stain 18 was used to visualize for iron, and Iba1 immunohistochemistry was used to visualize monocytes that infiltrated the tumor (macrophages). 2 We quantified the amount of Iba1 staining in the vehicle as well as the Amp B group by manually counting the number of cells using ImageJ. All the corners of the tumors were used in the cell counting to prevent selection bias. The number of cells within the field of view was normalized to the size of the tumor in that field of view.
For Experiment 2, we injected 100 µL of 500kDa fluorescein isothiocyanate (FITC)-dextran at 50mg/mL into the tail vein of the animals after the MRI. The FITC was allowed to circulate in the body for 1 hour before the mouse was sacrificed. The brains were removed and placed in 4% paraformaldehyde for 48 hours and then placed in 30% sucrose for 48 hours. The brain was then frozen and cut into 20-μm slices. The integrity of tumor and normal appearing brain blood vessels were examined and compared against each other under a fluorescence microscope.
MRI Data Analysis
Tumor volume was calculated manually using the T2w image with the ImageJ software. BBB breakdown was assessed quantitatively by taking the ratio of the signal intensity of the tumor and the signal intensity of the contralateral cortex for both the pre-and post-Gd image and then subtracting the two. Both vehicle as well as Amp B animals showed similar degrees of Gd enhancement on T1w images. T 2 * is sensitive to molecules that perturb the magnetic field (and are paramagnetic), such as Fe 2+ . Using the MEGE sequence, we calculated the T 2 * of the water within the entire tumor, as well as contralateral normal appearing tissue before and after ferumoxytol. Changes in T 2 * within the tumor were calculated by subtracting the pre-iron value from the post-iron value (obtained 24h post-iron injection). Due to the lack of tumor contrast on the MEGE sequence, the T2w sequence was used as a guide to draw the region of interest in the tumor. The change in T 2 * post-iron contrast was calculated as post-ferumoxytol T 2 * minus pre-ferumoxytol T 2 *. Changes in T 2 * for vehicle-or Amp B-treated animals were compared using Student's t-test.
Results
Animals in the vehicle group showed no obvious darkening, while those in the Amp B group had visually apparent darkening (Fig. 1A-D) . Using a region of interest that included the visible tumor, T 2 * values were compared in animals pre-and 24h postcontrast injection. Animals in the vehicle group showed no significant changes in T 2 * Fig. 1 Changes on the T 2 * map 24 hours after USPIO injection. There was no significant T 2 * darkening in the tumor of vehicle animals, but significant darkening in the tumor can be seen in Amp B-treated animals. The white region of interest demarcates the region of interest used for the tumor and the contralateral brain.
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before and after USPIO (P>.05, paired t-test), while the Amp B-treated animals showed significantly decreased T 2 * compared with pre-injection (P<.01, paired t-test). Figure 2 shows the average change in both tumor volume and T 2 * when comparing the Amp B group against the vehicles. The decline in tumor T 2 * in Amp B-treated animals shows that there is likely an increased accumulation of iron in the tumor 24 hours after USPIO injection. There were no significant changes in T 2 * values on the contralateral side of the brain in the Amp B-or vehicle-treated animals.
To rule out the possibility that the difference in T 2 * with Amp B reflects an opening of the BBB that may not exist in the vehicle group, we included a Gd-enhanced MRI study. There was significant BBB leakage in both vehicle-as well as Amp B-treated animals. Examining the normal appearing brain parenchyma, there were no signs of Gd leakage into the tissue (Fig. 3) .
Gadolinium is 950Da, so it is sensitive to relatively small disruptions in the BBB; however, it is possible that Amp B caused a large disruption in the tumor BBB. We tested this possibility using large, 500kDa FITC-dextran molecules that are slightly smaller than ferumoxytol, which is 750kDa. We found that the blood vessels in the apparently normal brain parenchyma are well defined and comparable to those found in the tumor (Fig. 4B and D) , suggesting that there is likely very little FITC leakage from the tumor vasculature. In these mice, we replicated our results and showed a decrease in tumor T 2 * that was similar in magnitude to ones reported in Experiment 1 ( Fig. 4A and C) .
We further validated our MRI results with histopathology by staining for infiltrated monocytes (macrophage) using Iba1, and by staining for iron using DAB-enhanced Perl's stain. The vehicle group showed minimal Iba1 staining within the tumor tissue, but there was abundant staining outside the tumor mass (Fig. 5) . In contrast, there was abundant Iba1 staining within and outside the tumor of the Amp B-treated group, which was significantly higher compared with vehicle controls (P<.05, Student's t-test). For paraffin sections, although it is difficult to resolve that the iron is colocalized with the Iba1-positive cells, iron staining was visible in tumor areas that also have abundant amounts of Iba1 staining (Fig. 6 ). We included a negative control for the iron staining, in which we skipped the iron localization step (incubation in HCl and potassium ferrocyanide). The negative control had no brown staining on the slide (not shown).
Discussion
While the incubation of cells with iron followed by their injection into animals has been used to track these labeled cells, the intravenous injection of USPIO has also been employed to label monocytes in other animal studies. Specifically, USPIO-MRI has been used in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis with significant inflammatory responses. It was shown that there was a decrease in signal on T 2 * weighted MRI in EAE, which was reduced after treatment with the anti-inflammatory drug lovastatin, 19 suggesting that USPIO uptake and MRI can be used to detect the activity of immune cell trafficking. Previous work, using fluorescently tagged USPIO , also found that there was significant T 2 * darkening post-injection with lipopolysaccharide (LPS), a strong immune stimulant, which was completely ablated when circulating monocytes were depleted using clodronate liposomes before treatment with LPS. 20 The authors then confirmed that the fluorescent USPIO was colocalized with F4/80-stained macrophages. This provided strong evidence that signal changes observed on T 2 * scans were predominantly caused by circulating monocytes that carried iron into the brain.
Our results of T 2 * and histology show that Amp B enhanced the transfer of iron into the brain tumor. The most likely cause was that monocyte phagocytosed the iron in the circulation and carried it into the tumor, as Amp B is known to increase monocyte activation and infiltration into intracranial GBM in mice. 2 Aside from being carried over by monocytes, the trafficking of USPIO could also come from a nonspecific movement 6 Histological staining in Amp B tumor for (A, C) macrophage/microglia (Iba1), and (B, D) DAB-enhanced Perl's (iron) staining on the adjacent paraffin slide. This shows that there are macrophages and microglia (brown cells) and that there is iron accumulation in the tumor (small brown spots). Scale = 100 μm. MRI data for this animal is shown in Fig. 2. of iron across the BBB. Ferumoxytol did not appear to leak into the tumor in the vehicle-treated animals, evident from the fact that there was no significant change in T 2 * postcontrast. Moreover, examining normal appearing brain parenchyma, we found no significant changes in T 2 * in the Amp B-treated animals, suggesting that Amp B did not cause a global increase in BBB permeability. Nonetheless, to rule out the possibility that Amp B caused a selective disruption of tumor BBB, we used Gd-enhanced MRI to assess the status of the BBB. We showed that the BBB disruption was localized to the tumor, and Gd enhancement was similar in both Amp B-and vehicle-treated animals.
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The phenomenon of brain tumors being permeable to Gd but not ferumoxytol has been reported in clinical studies measuring cerebral blood volume to evaluate pseudoprogression. It was shown that ferumoxytol does not leak into a Gd-permeable BBB and is a better blood pool agent to quantify cerebral blood volume. 24, 25 This can be attributed to their size difference, as Gd is a much smaller molecule than ferumoxytol (950Da vs 750kDa, respectively). However, this raises the possibility that Amp B treatment might be causing a disruption in the upper ranges of the BBB, allowing ferumoxytol to leak into the tumor.
To address this possibility, we used 500kDa FITC-dextran molecules to investigate the BBB of Amp B-treated animals. We found that blood vessels within the tumor of Amp B-treated animals appeared similar to the ones found in normal brain parenchyma with respect to how well the blood vessels were defined. This suggests that there is very little FITC leaking into the tumor.
Although there is evidence indicating that ferumoxytol does not leak across a tumor BBB acutely, it is still possible for ferumoxytol to cross the BBB via enhanced permeability and retention (EPR) effects. 26 We allowed the FITC to circulate for 1h, with the goal of giving time for unregulated diffusion across a broken BBB. This study paradigm could not discount the possibility of ferumoxytol entering the tumor via EPR over much longer time periods. It is possible that some of the contrast enhancement we observed is due to ferumoxytol entering the tumor via EPR. However, due to its short half-life, it was not possible to let FITC circulate longer to account for EPR effects.
Thus, we moved on to verify our hypothesis by histopathology. If changes in T 2 * were indeed related to monocyte phagocytosing ferumoxytol and subsequently migrating into the tumor, we should see an increase in the number of Iba1-positive cells in the tumor of Amp B-treated animals. In addition, we should see colocalization of Iba1 with iron staining.
Indeed, quantification of the number of Iba1-positive cells in the tumor showed an elevated number of Iba1 cells in the Amp B-treated animals compared with vehicle animals. The change is important to note, as Iba1 stains both resident microglia as well as infiltrated monocytes (macrophages). The increase in Iba1-positive cells in our study appeared less than previously reported. 2 This may be caused by the duration of treatment. We treated the current animals for only 7 days with Amp B, while the previous results were obtained after 40 days of Amp B treatment. The short treatment time used in our study likely accounts for why there was no significant difference in tumor volume between vehicle and Amp B animals.
Examining the iron and the Iba1 staining, it is difficult to claim that the 2 stains were colocalized in adjacent paraffin sections. However, iron signals were located around areas with high levels of Iba1 staining, suggesting that USPIOs are engulfed by phagocytic cells. This supports our hypothesis that ferumoxytol was engulfed by monocytes in the blood and carried across into the tumor tissue, suggesting that changes in T 2 * were detecting the migration of monocytes.
We provided evidence that the Amp B-induced increase in monocyte infiltration into the tumor can be detected with ferumoxytol using T 2 * mapping. However, it must be pointed out that the objective of our manuscript is to show proof of principle, so it does not address whether this Amp B-related treatment phenomenon is associated with future tumor shrinkage. Our work is the first step to potentially demonstrate that ferumoxytol can be used to detect the efficacy of innate immune stimulating therapies, but more work is needed to fully establish the relationship between T 2 *, monocyte infiltration, and tumor control.
In conclusion, we showed that USPIO-MRI can be used as a rapid method to detect pharmacologically induced increases in monocyte infiltration into brain tumors. We observed a treatment-associated phenomenon with as little as 7 days of treatment; this method should be applicable to any drug that affects innate immunity. We showed that the effects of immune stimulating drugs can be detected in the context of GBM. This is a promising technique, and further work is needed to consolidate the relationship between USPIO-MRI findings and prognosis. 
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